Equities research analysts predict that Celgene Co. (NASDAQ:CELG) will report $1.94 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Celgene’s earnings, with the lowest EPS estimate coming in at $1.88 and the highest estimate coming in at $2.04. Celgene posted earnings per share of $1.61 during the same quarter last year, which indicates a positive year over year growth rate of 20.5%. The business is expected to issue its next earnings results before the market opens on Thursday, January 25th.
On average, analysts expect that Celgene will report full year earnings of $7.37 per share for the current financial year, with EPS estimates ranging from $7.30 to $7.46. For the next financial year, analysts anticipate that the company will post earnings of $8.84 per share, with EPS estimates ranging from $8.35 to $9.47. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover Celgene.
Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the business earned $1.58 EPS.
CELG has been the subject of a number of recent research reports. Morgan Stanley downgraded Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a research note on Thursday, October 5th. Sanford C. Bernstein lowered Celgene from an “outperform” rating to a “market perform” rating and set a $121.00 price target for the company. in a research report on Wednesday, December 27th. BTIG Research reiterated a “hold” rating on shares of Celgene in a research report on Sunday, October 22nd. Cantor Fitzgerald reiterated a “hold” rating and set a $112.00 price target on shares of Celgene in a research report on Monday, October 30th. Finally, Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target for the company in a research report on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Celgene currently has an average rating of “Buy” and a consensus price target of $129.98.
Several institutional investors have recently made changes to their positions in CELG. Winslow Evans & Crocker Inc. lifted its holdings in shares of Celgene by 25.6% during the fourth quarter. Winslow Evans & Crocker Inc. now owns 11,780 shares of the biopharmaceutical company’s stock valued at $1,229,000 after purchasing an additional 2,404 shares during the last quarter. Ingalls & Snyder LLC lifted its holdings in shares of Celgene by 112.0% during the fourth quarter. Ingalls & Snyder LLC now owns 57,231 shares of the biopharmaceutical company’s stock valued at $5,973,000 after purchasing an additional 30,230 shares during the last quarter. TRUE Private Wealth Advisors purchased a new stake in shares of Celgene during the fourth quarter valued at $241,000. State of Alaska Department of Revenue lifted its holdings in shares of Celgene by 1,777.2% during the fourth quarter. State of Alaska Department of Revenue now owns 80,437 shares of the biopharmaceutical company’s stock valued at $8,393,000 after purchasing an additional 76,152 shares during the last quarter. Finally, Syntal Capital Partners LLC purchased a new stake in shares of Celgene during the fourth quarter valued at $407,000. Institutional investors and hedge funds own 79.85% of the company’s stock.
Shares of Celgene (NASDAQ:CELG) traded up $0.93 on Tuesday, reaching $102.65. The company had a trading volume of 7,714,583 shares, compared to its average volume of 6,700,000. The company has a market cap of $80,820.00, a P/E ratio of 24.21, a P/E/G ratio of 0.66 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene has a 52-week low of $94.55 and a 52-week high of $147.17.
COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Expect Celgene Co. (CELG) to Post $1.94 EPS” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/22/zacks-analysts-expect-celgene-co-celg-to-post-1-94-eps.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Get a free copy of the Zacks research report on Celgene (CELG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.